Professor NG Oi Lin, Irene

Prof NG

Loke Yew Professor in Pathology
Chair Professor of Pathology
Director, State Key Laboratory of Liver Research (HKU)

Molecular pathology, hepatopathology and molecular oncology

  • MBBS, MD, PhD HK, FRCPath, FHKCPath, FHKAM (Pathology)

Molecular pathology, hepatopathology and molecular oncology

Research Description
The research of my lab aims to unravel the molecular and cellular mechanisms of liver cancer. The current research of my lab focuses on the integrated functional genomics of liver cancer using genome-scale technologies coupled with clinical translational studies. I have an active program in the basic/translational research of liver cancer, using state-of-the art molecular approaches including genomics, transcriptomics, and single cell analysis, to capture cancer heterogeneity, identify novel subclones, and unravel signaling pathways. I am coupling genomics, genetics, functional molecular analysis and in vivo pre-clinical animal models as well as patient-derived tumor xenograft models to address the molecular mechanisms of this cancer. We work towards translational application for early detection, diagnosis, prognosis and patient stratification towards precision oncology.

Research Grants in the recent 5 years
  • RGC Theme-based Research Scheme on Research Fund on Understanding cancer stemness in liver cancer- From regulation to translational applications (2016)
  • RGC General Research Fund on liver cancer (2011, 2013, 2014, 2015 & 2016)
  • Health and Medical Research Fund on HBV and liver cancer (2013, 2015 2016 & 2017)
  • Innovation and Technology Commission Grant for State Key Lab of Liver Research (2010 – present)
  • Ministry of Science and Technology grant on liver cancer (2017)

Research team members
  • Dr. Lo-Kong Chan (Research Assistant Professor)
  • Dr. Daniel WH Ho (Research Assistant Professor)
  • Dr. Karen MF Sze (Assistant Research Officer)
  • Dr. Ao Chen (Post-doctoral Fellow)
  • Dr. Elley YT Chiu (Post-doctoral Fellow)
  • Dr. Abdullah Hussain (Post-doctoral Fellow)
  • Dr. Yu-Man Tsui (Post-doctoral Fellow)
  • Dr. Alexia Xia Wang (Post-doctoral Fellow)
  • Dr. Vanilla Xin Zhang (Post-doctoral Fellow)
  • Dr. Qingyang Zhang (Post-doctoral Fellow)
  • Mr. Hong-Yang Huang (PhD student)
  • Ms. Lucy Lu Tian (PhD student)
  • Ms. Xiao-Yu Xie (PhD student)
  • Ms. Joyce MF Lee (Senior Technician)
  • Ms. Eva Lee (Technical Officer)
  • Mr. Ivan Ka Kit Tam (Senior Technical Assistant)
  • Mr. Cheuk Hang Gary Cheung (Research Assistant)
  • Ms Xueying Lyu (Research Assistant)
  • Ms. Vanessa Sheung-In Ming (Research Assistant)
  • Ms. Mary Suarez (Research Assistant)


Awards and Honors

The World Academy of Science 2014 Prize (Medical Science)

Director, State Key Laboratory of Liver Research (HKU)

Loke Yew Endowed Professorship in Pathology

Croucher Senior Medical Research Fellowship 2013-14 and 2005- 06, Croucher Foundation

Director, Croucher Summer Course in Cancer Biology (2013, 2015 & 2017)

Faculty Outstanding Research Output Award 2012 & 2019, HKU

Outstanding Research Student Supervisor Award 2007-08, HKU

Outstanding Researcher Award 2005, HKU


Selected Publications
  • Sze KM#, Ho DW#, Chiu YT, Tsui YM, Chan LK, Lee JM, Chok KS, Chan AC, Tang CN, Tang VW, Lo IL, Yau DT, Cheung TT, Ng IO. Novel cis-activation harnessing host ELF4 and HBV integrated at the TERT promoter to enhance hepatocarcinogenesis. Hepatology 2021;73:23-40. #Equal contribution.

  • Chan LK, Ng IO. Joining the dots for better liver cancer treatment. Nat Rev Gastroenterol Hepatol 2020; 17:74-75.
  • Ho DW#, Tsui YM#, Sze KM, Chan LK, Cheung TT, Lee E, Sham PC, Tsui SK, Lee TK, Ng IO. Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. Cancer Lett 2019; 459:176-185. #Equal contribution.
  • Tsang FH, Law CT, Tang CT, Cheng CL, Chin DW, Tam VW, Wei L, Wong CC, Ng IO*, Wong CM*. Aberrant super-enhancer landscape in human hepatocellular carcinoma. Hepatology 2019; 69:2502-2517. *Co-corresponding authors.
  • Lee D, Xu IM, Chiu DK, Leibold J, Tse AP, Chan CY, Lai RK, Cheung TT, Chok SH, Wong CM, Lowe S, Ng IO*, Wong CC*. Induction of oxidative stress via inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma. Hepatology 2019; 69:1768-1786. *Co-corresponding authors.
  • Ma W#, Ho DW#, Sze KM#, Tsui YM, Chan LK, Lee JM, Ng IO. APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity. Mol Carcinog 2019; 58:643-653. #Equal contribution.
  • Wong CM#, Tsang FH#, Ng IO. Regulatory RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol 2018; 15:137-151. #Equal contribution.
  • Cheng BY, Lau EY, Leung DH, Ho NP, Cheng LK, Ma S, Lin CH, Lo RC, Ng IO*, Lee TK*. IRAK1 augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Res 2018; 78:2332-2342. *Co-corresponding authors.
  • Ho DW#, Chan LK#, Chiu EY, Xu IM, Poon RT, Cheung TT, Lo IL, Lam PW, Tang CN, Tang VW, Yau DT, Li MX, Wong CM, Ng IO. Exome and targeted sequencing identifies frequent TSC 1 and 2 mutations in HBV-associated hepatocellular carcinoma with high sensitivity to mTOR inhibitor treatment. Gut 2017; 66:1496-1506. #Equal contribution.
  • Cui CP, Wong CC, Kai AK, Ho DW, Lau EY, Tsui YM, Chan LK, Cheung TT, Chok KS, Chan AC, RC Lo, Lee JM, Lee TK, Ng IO. SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop. Gut 2017; 2017; 66:2149-2159.
  • Ma MK#, Lau EY#, Lo J, Ho NP, Ma S, Lin CH, Copland JA, Ding J, Lo RC, Ng IO*, Lee TK*. Targeting liver-tumor initiating cells via hampering Stearoyl-CoA Desaturase (SCD1) mediated ER stress. J Hepatol 2017; 67:979-990. #Equal contribution. *Co-corresponding authors.
  • Xu IM, Lai RK, Lin SH, Tse AP, Chiu DK, Koh HY, Law CT, Wong CM, Cai ZW, Wong CC*, Ng IO*. Transketolase counteracts oxidative stress to drive cancer development. Proc Natl Acad Sci USA 2016;113:E725-34. *Co-corresponding authors.
  • Kai AK, Chan LK, Lo RC, Lee JM, Wong CC, Wong CM, Ng IO. Downregulation of TIMP2 via HIF-1/ miR-210/HIF-3 regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology 2016; 64:473-87.
  • Chiu YT#, Wong JK#, Choi SW, Sze KM, Ho DW, Chan LK, Man K, Cherny S, Yang WL, Wong CM*, Sham PC*, Ng IO*. Novel pre-mRNA splicing of intronic integrated HBV in generation of oncogenic chimera in hepatocellular carcinoma. J Hepatol 2016; 64: 1256-64. #Equal contribution. *Co-corresponding authors.
  • Wong CM*, Lai W, Law CT, Ho DW, Tsang FH, Au SL, Sze KM, Lee JM, Wong CC, Ng IO*. Upregulation of histone methyltransferase SETDB1 expression by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. Hepatology 2016; 63:474-87. *Co-corresponding authors.
  • Lo J, Lau EY, Ching RH, Ng IO*, Lee TK*. NF-KB mediated CD47 upregulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma. Hepatology 2015; 62: 534–545. *Co-corresponding authors.
  • Lee TK*#, Cheung VC#, Lu P, Lau EY, Ma S, Tang KH, Tong C, Ng IO*. Blockade of CD47 mediated CTSS-PAR2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 2014;60:179-91. *Co-corresponding authors. #Equal contribution.
  • Wong CC, Tse AP, Huang YP, Zhu YT, Chiu DK, Au SL, Kai AK, Lee JM, Wei LL, Tsang FH, Lo RC, Shi J, Zheng YP, Wong CM, Ng IO. Deregulation of Lysyl Oxidase-Like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma metastasis. Hepatology 2014; 60:1645-58.
  • Sze KM, Chu GK, Mak QH, Lee JM, Ng IO. Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has suppressive role in mitotic checkpoint signaling in HCC. J Pathol 2014; 233:51-60.
  • Wong CM#, Wong CC#, Lee JMF, Fan DNY, Au SLK, Ng IO. Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 2012; 55:1453-61.  (Featured on cover) (Faculty of 1000 (F1000) - the top 2% of published articles in biology and medicine). #Equal contribution.
  • Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO*. CD24+ liver tumor-initiating cells drive self-renewal and tumor initiation through Stat3-mediated nanog regulation. Cell Stem Cell 2011; 9:50-63.
  • Wong CC, Wong CM, Tung EKK, Au SLK, Lee JMF, Man K, Ng IO. MiR-139 suppresses metastasis and progression of hepatocellular carcinoma through regulation of Rho-kinase 2 (ROCK2). Gastroenterology 2011;140:322-31. (Top 2% of published articles in biology and medicine, Faculty of 1000).
  • Sze KM#, Wong KL#, Chu GK, Yau TO, Ng IO. Loss of PTEN enhances cell invasion and migration through AKT/Sp-1 transcription factor/MMP2 activation and has clinicopathologic significance in hepatocellular carcinoma. Hepatology 2011;53:1558-69. #Equal contribution.
  • Chan DW, Chan CY, Yam JWP, Ching YP, Ng IO. Prickle-1 promotes degradation of Dishevelled by ubiquitination in liver cancer. Gastroenterology 2006; 131:1218-27.
  • Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, Jin DY, Ng IO. Deleted in liver cancer 2, DLC2, suppresses cell transformation via inhibition of RhoA activity. Proc Natl Acad Sci USA 2005;102;15207-12.
  • Wong CM, Yam JW, Ching YP, Leung TH, Yau TO, Jin DY, Ng IO. Rho GTPase activating protein DLC1 (deleted in liver cancer) suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res 2005; 65: 8861-8868.

Editorships

Hepatology (Associate Editor)

Journal of Hepatology

Gastroenterology (International Consultant)

Liver Cancer

Cellular and Molecular Gastroenterology and Hepatology

EBioMedicine

Oncogenesis

Genes and Cancer

Liver Cancer International